P&G (PG) Didn't Exercise Option to Develop, Commercialize Doxepin OTC Product with Somaxon (SOMX)
Go back to P&G (PG) Didn't Exercise Option to Develop, Commercialize Doxepin OTC Product with Somaxon (SOMX)| Procter & Gamble (NYSE: PG) | Delayed: 142.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.97 | 52 Week High | $90.33 | |||
| Open | $142.97 | 52 Week Low | $74.01 | |||
| Day High | $142.97 | P/E | 38.54 | |||
| Day Low | $142.97 | EPS | $3.71 | |||
| Volume | 7,837 | |||||
| SOMAXON PHARMA (NASDAQ: SOMX) | Delayed: 3.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.00 | 52 Week High | $3.17 | |||
| Open | $3.00 | 52 Week Low | $0.22 | |||
| Day High | $3.00 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $-3.05 | |||
| Volume | 300 | |||||
